In Europe, bicalutamide monotherapy with a dose of 150 mg/d is a widely used option for prostate cancer patients who wish to avoid the consequences of standard androgen deprivation using an LHRH agoni… more →
THE "NEW" PROSTATE CANCER INFOLINKSitemaster wrote 1 week ago: In Europe, bicalutamide monotherapy with a dose of 150 mg/d is a widely used option for prostate can … more →
Sitemaster wrote 1 week ago: According to a report from the Associated Press, generic bicalutamide (the generic form of Casodex) … more →
Sitemaster wrote 2 months ago: In today’s news reports we address such issues as: The possibility that type of initial treat … more →
Sitemaster wrote 3 months ago: The reports addressed today offer information from three very technical studies dealing with: Genom … more →
Sitemaster wrote 11 months ago: Newly published studies today include data on: Risk for patients with prostate atypia on biopsy hav … more →
havis23 wrote 1 year ago: prostate cancer disease in which cancer develops in the prostate, a gland in the malereproductive s … more →